Progression of Tricuspid Regurgitation After Surgery for Ischemic Mitral Regurgitation.
Date
2021-02
Journal Title
Journal ISSN
Volume Title
Repository Usage Stats
views
downloads
Citation Stats
Abstract
Background
Whether to repair nonsevere tricuspid regurgitation (TR) during surgery for ischemic mitral valve regurgitation (IMR) remains uncertain.Objectives
The goal of this study was to investigate the incidence, predictors, and clinical significance of TR progression and presence of ≥moderate TR after IMR surgery.Methods
Patients (n = 492) with untreated nonsevere TR within 2 prospectively randomized IMR trials were included. Key outcomes were TR progression (either progression by ≥2 grades, surgery for TR, or severe TR at 2 years) and presence of ≥moderate TR at 2 years.Results
Patients' mean age was 66 ± 10 years (67% male), and TR distribution was 60% ≤trace, 31% mild, and 9% moderate. Among 2-year survivors, TR progression occurred in 20 (6%) of 325 patients. Baseline tricuspid annular diameter (TAD) was not predictive of TR progression. At 2 years, 37 (11%) of 323 patients had ≥moderate TR. Baseline TR grade, indexed TAD, and surgical ablation for atrial fibrillation were independent predictors of ≥moderate TR. However, TAD alone had poor discrimination (area under the curve, ≤0.65). Presence of ≥moderate TR at 2 years was higher in patients with MR recurrence (20% vs. 9%; p = 0.02) and a permanent pacemaker/defibrillator (19% vs. 9%; p = 0.01). Clinical event rates (composite of ≥1 New York Heart Association functional class increase, heart failure hospitalization, mitral valve surgery, and stroke) were higher in patients with TR progression (55% vs. 23%; p = 0.003) and ≥moderate TR at 2 years (38% vs. 22%; p = 0.04).Conclusions
After IMR surgery, progression of unrepaired nonsevere TR is uncommon. Baseline TAD is not predictive of TR progression and is poorly discriminative of ≥moderate TR at 2 years. TR progression and presence of ≥moderate TR are associated with clinical events. (Comparing the Effectiveness of a Mitral Valve Repair Procedure in Combination With Coronary Artery Bypass Grafting [CABG] Versus CABG Alone in People With Moderate Ischemic Mitral Regurgitation, NCT00806988; Comparing the Effectiveness of Repairing Versus Replacing the Heart's Mitral Valve in People With Severe Chronic Ischemic Mitral Regurgitation, NCT00807040).Type
Department
Description
Provenance
Citation
Permalink
Published Version (Please cite this version)
Publication Info
Bertrand, Philippe B, Jessica R Overbey, Xin Zeng, Robert A Levine, Gorav Ailawadi, Michael A Acker, Peter K Smith, Vinod H Thourani, et al. (2021). Progression of Tricuspid Regurgitation After Surgery for Ischemic Mitral Regurgitation. Journal of the American College of Cardiology, 77(6). pp. 713–724. 10.1016/j.jacc.2020.11.066 Retrieved from https://hdl.handle.net/10161/22842.
This is constructed from limited available data and may be imprecise. To cite this article, please review & use the official citation provided by the journal.
Collections
Scholars@Duke
Peter Kent Smith
Dr. Smith is the Principal Investigator for the Duke site in the Cardiothoracic Surgery Clinical Trials Network (CTSN) and in recent years has focused his research efforts in clinical research. The CTSN is an NHLBI sponsored network developed to promote clinical research in cardiac surgery, and is now entering its 7th year of funding with a commitment now for an additional 5 years. Dr. Smith is the national PI for a randomized clinical trial comparing CABG alone to CABG with mitral repair for moderate ischemic mitral regurgitation. This trial is nearing completion of enrollment, and he is now the PI of a clinical trial of FFR vs angiographically guided CABG expected to begin national enrollment in September of 2013. Duke has participated as a site in 3 additional CTSN trials, and is one of two sites awarded NHLBI funding as a Clinical Skills Education Core. This funding is designed to formally develop surgical clinical trialists and promote clinical research capacity within our specialty. The Duke site has thus far sponsored 6 CTSN scholars who have all received Masters degrees in clinical research, participated in CTSN protocols and other activities of the Network. Additionally, Dr. Smith has been awarded site funding from the Veteran’s Administration to begin VA cooperative clinical research trials at the Durham VA. Through all of these activities, an integration of clinical research, publications, and scholarship with the advancement of clinically effective Thoracic Surgery is the goal.
Unless otherwise indicated, scholarly articles published by Duke faculty members are made available here with a CC-BY-NC (Creative Commons Attribution Non-Commercial) license, as enabled by the Duke Open Access Policy. If you wish to use the materials in ways not already permitted under CC-BY-NC, please consult the copyright owner. Other materials are made available here through the author’s grant of a non-exclusive license to make their work openly accessible.